Aptose Biosciences Inc. (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities. The Company develops therapeutics focused on epigenetic processes and signal transduction abnormalities at the edge of cancer research, coupled with companion diagnostics to identify the optimal patient population for its products. The Company's APTO-253 is a small molecule that can induce expression of the genes that codes for the Kruppel-like factor 4 (KLF4) master transcription factor and the p21 cell cycle inhibitor protein.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: N/A
- Sub-Industry: N/A
- Symbol: NASDAQ:APTO
- CUSIP: N/A
- Web: www.aptose.com
- Market Cap: $19.6 million
- Outstanding Shares: 18,849,000
- 50 Day Moving Avg: $1.02
- 200 Day Moving Avg: $1.09
- 52 Week Range: $0.78 - $4.30
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -1.65
- P/E Growth: 0.00
- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: $0.46 per share
- Price / Book: 2.26
- EBIDTA: ($13,200,000.00)
- Return on Equity: -139.94%
- Return on Assets: -121.78%
- Current Ratio: 5.29%
- Quick Ratio: 5.29%
- Average Volume: 416,364 shs.
- Beta: 1.29
- Short Ratio: 1.66
Frequently Asked Questions for Aptose Biosciences (NASDAQ:APTO)
What is Aptose Biosciences' stock symbol?
Aptose Biosciences trades on the NASDAQ under the ticker symbol "APTO."
How were Aptose Biosciences' earnings last quarter?
Aptose Biosciences Inc (NASDAQ:APTO) posted its quarterly earnings results on Tuesday, March, 29th. The company reported ($0.38) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.28) by $0.10. View Aptose Biosciences' Earnings History.
Where is Aptose Biosciences' stock going? Where will Aptose Biosciences' stock price be in 2017?
4 analysts have issued 12-month price objectives for Aptose Biosciences' stock. Their forecasts range from $7.00 to $12.00. On average, they anticipate Aptose Biosciences' share price to reach $9.00 in the next twelve months. View Analyst Ratings for Aptose Biosciences.
What are analysts saying about Aptose Biosciences stock?
Here are some recent quotes from research analysts about Aptose Biosciences stock:
- 1. Canaccord Genuity analysts commented, "CATB reported 3/31 cash of $38.5MM, sufficient to fund operations into Q2:18." (5/12/2017)
- 2. According to Zacks Investment Research, "Aptose Biosciences Inc. is a clinical-stage biotechnology company. The company is advancing therapeutics to treat life-threatening cancers, such as acute myeloid leukemia, high-risk myelodysplastic syndromes and other hematologic malignancies. Its lead program APTO-253 has completed a Phase 1 study in patients with solid tumors. Aptose Biosciences Inc., formerly known as Lorus Therapeutics Inc., is headquartered in Toronto, Canada. " (11/17/2016)
- 3. Oppenheimer Holdings Inc. analysts commented, "Aptose announced June 8 an agreement with CrystalGenomics for an exclusive global option and license for CrystalGenomics’ CG026806. CG026806 is a non- covalent small molecule inhibitor of Bruton’s tyrosine kinase (BTK), FMS-like tyrosine kinase 3 (FLT3) and the Aurora kinases (AURK). Aptose will make its decision on its option mid-2017 after executing IND-enabling studies. We reiterate our Outperform rating and $17 price target." (6/9/2016)
Are investors shorting Aptose Biosciences?
Aptose Biosciences saw a increase in short interest in April. As of April 13th, there was short interest totalling 972,759 shares, an increase of 6.0% from the March 31st total of 917,384 shares. Based on an average daily trading volume, of 176,606 shares, the short-interest ratio is presently 5.5 days.
Who are some of Aptose Biosciences' key competitors?
Some companies that are related to Aptose Biosciences include Catasys (CATS), Bio-Path Holdings (BPTH), Histogenics Corp (HSGX), Chiasma (CHMA), Nivalis Therapeutics (NVLS), Critical Outcome T (COTQF), Electromed (ELMD), HTG Molecular Diagnostics (HTGM), EnteroMedics (ETRM), OHR Pharmaceutical (OHRP), Fibrocell Science (FCSC), Threshold Pharmaceuticals (THLD), Tonix Pharmaceuticals Holding Corp. (TNXP), OmniComm Systems (OMCM), Can Fite Biopharma Ltd (CANF), Soleno Therapeutics (SLNO), Check Cap Ltd (CHEK) and Cesca Therapeutics (KOOL).
Who are Aptose Biosciences' key executives?
Aptose Biosciences' management team includes the folowing people:
- William Glenn Rice, Chairman of the Board, President, Chief Executive Officer
- Gregory Kwok Lee Chow, Chief Financial Officer, Senior Vice President
- Denis R. Burger Ph.D., Independent Director
- Erich M. Platzer M.D., Ph.D., Independent Director
- Bradley Thompson, Independent Director
- Mark D. Vincent M.D., Independent Director
- Warren Whitehead, Independent Director
How do I buy Aptose Biosciences stock?
Shares of Aptose Biosciences can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Aptose Biosciences' stock price today?
MarketBeat Community Rating for Aptose Biosciences (NASDAQ APTO)MarketBeat's community ratings are surveys of what our community members think about Aptose Biosciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Aptose Biosciences stock can currently be purchased for approximately $1.04.
Earnings History for Aptose Biosciences (NASDAQ:APTO)Earnings History by Quarter for Aptose Biosciences (NASDAQ:APTO)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Earnings Estimates for Aptose Biosciences (NASDAQ:APTO)
Current Year EPS Consensus Estimate: $-1.45 EPS
Next Year EPS Consensus Estimate: $-0.63 EPS
Dividend History for Aptose Biosciences (NASDAQ:APTO)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Aptose Biosciences (NASDAQ:APTO)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Aptose Biosciences (NASDAQ:APTO)
Latest Headlines for Aptose Biosciences (NASDAQ:APTO)
|Form 6-K Aptose Biosciences Inc. For: May 11 - StreetInsider.com|
www.streetinsider.com - May 12 at 4:10 PM
|Aptose Biosciences Inc (APTO) Receives Buy Rating from Canaccord Genuity|
www.americanbankingnews.com - May 12 at 4:05 PM
|Investor Network: Aptose Biosciences Inc. to Host Earnings Call|
finance.yahoo.com - May 12 at 2:04 AM
|Aptose Reports Results for the First Quarter Ended March 31, 2017|
finance.yahoo.com - May 12 at 2:04 AM
|Aptose Reports Results for the First Quarter Ended March 31, 2017 - GlobeNewswire (press release)|
globenewswire.com - May 11 at 9:03 PM
|Preclinical Data on Aptose Biosciences FLT3/BTK Inhibitor CG'806 Presented at AACR Hematologic Malignancies ... - GlobeNewswire (press release)|
globenewswire.com - May 8 at 8:34 PM
|Aptose Biosciences Inc (APTO) Sees Significant Growth in Short Interest|
www.americanbankingnews.com - May 8 at 8:52 AM
|Aptose Biosciences (APTO) Receiving Favorable Press Coverage, AlphaOne Reports|
www.americanbankingnews.com - April 29 at 9:56 AM
|Aptose Biosciences (APTO) Receives Media Impact Score of 0.56|
www.americanbankingnews.com - April 26 at 11:40 AM
|Aptose To Release First Quarter Ended March 31, 2017 Financial Results and Hold Conference Call on May 11, 2017 - Yahoo Finance|
finance.yahoo.com - April 25 at 3:34 PM
|Form 6-K Aptose Biosciences Inc. For: Apr 25 - StreetInsider.com - StreetInsider.com|
www.streetinsider.com - April 25 at 3:34 PM
|Aptose Biosciences to Participate at the Bloom Burton & Co. Healthcare Investor Conference 2017|
finance.yahoo.com - April 25 at 10:12 AM
|Aptose To Release First Quarter Ended March 31, 2017 Financial Results and Hold Conference Call on May 11, 2017|
finance.yahoo.com - April 24 at 10:41 AM
|Aptose Biosciences to Present CG'806 Data at AACR Hematologic Malignancies Meeting - GlobeNewswire (press release)|
www.globenewswire.com - April 20 at 1:42 AM
|Aptose Biosciences to Present CG'806 Data at AACR Hematologic ... - GlobeNewswire (press release)|
globenewswire.com - April 19 at 3:38 PM
|Aptose Biosciences to Present CG'806 Data at AACR Hematologic Malignancies Meeting|
feeds.benzinga.com - April 19 at 8:58 AM
|Aptose Biosciences to Present CG’806 Data at AACR Hematologic Malignancies Meeting|
finance.yahoo.com - April 19 at 8:32 AM
|Aptose Biosciences (APTO) Earns Daily Coverage Optimism Score of 0.31|
www.americanbankingnews.com - April 15 at 9:45 AM
|Aptose Reports Fourth Quarter and Year End 2016 Results|
us.rd.yahoo.com - March 28 at 8:37 PM
|How These Biotech Stocks are Faring? -- Actinium Pharma, Eleven Biotherapeutics, Neuralstem, and Aptose Biosciences - PR Newswire (press release)|
www.prnewswire.com - March 27 at 8:12 AM
|Aptose Biosciences (APTO) Announces Planned Departure of CBO Avanish Vellanki - StreetInsider.com|
www.streetinsider.com - March 27 at 8:12 AM
|Aptose Biosciences (APTO) Presents At Cowen and Company 37th Annual Health Care Conference|
seekingalpha.com - March 9 at 3:58 PM
|Aptose to Participate in Upcoming Investor Conferences|
feeds.benzinga.com - March 2 at 7:54 AM
|Aptose Biosciences to Present at Canaccord Genuity Rare Disease Biopharma 1x1 Day - Nasdaq|
www.nasdaq.com - February 2 at 3:38 PM
|Aptose Biosciences to Present at Canaccord Genuity Rare Disease Biopharma 1x1 Day|
finance.yahoo.com - February 2 at 3:38 PM
|Aptose Delays Lead Cancer Drug Development (APTO)|
www.investopedia.com - January 27 at 4:25 PM
|Aptose Shifts Focus, Delays Cancer Drug Development|
www.investopedia.com - January 27 at 4:25 PM
|Aptose Bio (APTO) to Prioritize Development of CG'806 and Temporarily Delay Clinical Activities with APTO-253|
www.streetinsider.com - January 23 at 8:50 PM
|7:02 am Aptose Biosciences will temporarily delay clinical activities with APTO-253 in order to elucidate the cause of recent manufacturing setbacks related to the intravenous formulation of APTO-253|
us.rd.yahoo.com - January 23 at 8:50 PM
|Form 6-K Aptose Biosciences Inc. For: Jan 23 - StreetInsider.com|
www.streetinsider.com - January 23 at 3:40 PM
Aptose Biosciences (APTO) Chart for Monday, May, 29, 2017